GH therapy has subsequently been approved in the USA and Europe for other pediatric conditions that result in short stature, including Turner syndrome, being born small for gestational age (SGA) with failure to attain normal growth, Prader-Willi syndrome, chronic renal insufficiency, short stature homeobox-containing gene (SHOX) deficiency, and, in the USA but not Europe, Noonan syndrome and idiopathic short stature [1, 4–11]. The gene discussed is GH1; the disease is chronic kidney disease.